These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21890570)

  • 1. Probable warfarin and dapsone interaction.
    Truong T; Haley J
    Clin Appl Thromb Hemost; 2012; 18(1):107-9. PubMed ID: 21890570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
    Spangler ML; Saxena S
    Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probable interaction between warfarin and torsemide.
    Bird J; Carmona C
    Ann Pharmacother; 2008 Dec; 42(12):1893-8. PubMed ID: 19017829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tobacco on INR.
    Garry J; Geraets DR
    Am J Health Syst Pharm; 2007 Apr; 64(8):804; author reply 805. PubMed ID: 17420191
    [No Abstract]   [Full Text] [Related]  

  • 5. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.
    Lee R; Wen A; Berube C
    Am J Health Syst Pharm; 2011 May; 68(9):814-7. PubMed ID: 21515865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated international normalized ratio values associated with concomitant use of warfarin and ceftriaxone.
    Clark TR; Burns S
    Am J Health Syst Pharm; 2011 Sep; 68(17):1603-5. PubMed ID: 21856805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed warfarin induced skin necrosis in a patient with poor warfarin metabolizing activity due to interrupted warfarin therapy.
    Gaikwad T; Ghosh K; Shetty S
    Eur J Clin Pharmacol; 2013 Feb; 69(2):293-4. PubMed ID: 22706625
    [No Abstract]   [Full Text] [Related]  

  • 11. A potential interaction between warfarin and atovaquone.
    Hidalgo K; Lyles A; Dean SR
    Ann Pharmacother; 2011 Jan; 45(1):e3. PubMed ID: 21189363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin resistance.
    Sinxadi P; Blockman M
    Cardiovasc J Afr; 2008; 19(4):215-7. PubMed ID: 18776969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases
.
    Shibata S; Takahashi H; Baba A; Takeshita K; Atsuda K; Matsubara H; Echizen H
    Int J Clin Pharmacol Ther; 2017 May; 55(5):449-452. PubMed ID: 28157069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated international normalized ratio associated with use of dronedarone and warfarin.
    Pogge EK; Haber SL
    Ann Pharmacother; 2011 Sep; 45(9):e46. PubMed ID: 21811004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible interaction between warfarin and Lycium barbarum L.
    Lam AY; Elmer GW; Mohutsky MA
    Ann Pharmacother; 2001 Oct; 35(10):1199-201. PubMed ID: 11675844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential interaction between telithromycin and warfarin.
    Kolilekas L; Anagnostopoulos GK; Lampaditis I; Eleftheriadis I
    Ann Pharmacother; 2004 Sep; 38(9):1424-7. PubMed ID: 15280511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probable interaction between warfarin and bee pollen.
    Hurren KM; Lewis CL
    Am J Health Syst Pharm; 2010 Dec; 67(23):2034-7. PubMed ID: 21098375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interaction between warfarin and oral miconazole gel].
    Ogard CG; Vestergaard H
    Ugeskr Laeger; 2000 Oct; 162(41):5511. PubMed ID: 11068529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.